- Acquired by Notable Labs, Feb 2023
- Raised $40M funding round, Oct 2010
- Raised $16.9M funding round, Dec 2021
About
VBL has developed its Monocyte Targeting Technology (MTT), as an investigational new and specific way to limit chronic inflammation. Its program is based on the discovery of a novel target protein that is selectively expressed on the surface of monocytes and controls their ability to migrate (or 'walk' to) inflamed tissues. This protein is called MOSPD2 (the "mono-walk" receptor).
The company's lead MTT candidate, VB-601, is an investigational proprietary monoclonal antibody that binds the MOSPD2 ("mono-walk") receptor and is engineered to specifically block the ability of monocytes to reach inflamed tissues. VB-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents, most of which target pro-inflammatory molecules and work through T and B lymphocytes but are not targeted to the monocyte cells.
Based on pre-clinical and human ex-vivo data, VB-601 has potential utility in a wide range of immune-inflammatory diseases, such as multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, non-alcoholic steatohepatitis (NASH), inflammatory bowel disease and other immune-inflammatory diseases.
Funding history · 3 rounds · $109.8M total
Q&A
- What is VBL Therapeutics' current status?
- VBL Therapeutics was acquired by Notable Labs in February 2023.
- What is VBL Therapeutics' primary focus?
- VBL Therapeutics focuses on targeted therapies for immune-inflammatory diseases, utilizing its Monocyte Targeting Technology (MTT) to limit chronic inflammation.
- What is the name of VBL Therapeutics' lead MTT candidate?
- The company's lead MTT candidate is VB-601, an investigational proprietary monoclonal antibody designed to block monocytes from reaching inflamed tissues.
- What is the total amount of funding VBL Therapeutics has raised?
- VBL Therapeutics has raised a total of $109,770,000 in funding.
- When did VBL Therapeutics receive its most recent grant?
- VBL Therapeutics received a grant of $2,820,000 in December 2021 from the EIC Accelerator Programme.
- Which investors participated in VBL Therapeutics' October 2010 funding round?
- In October 2010, VBL Therapeutics received funding from investors including.
- How many employees does VBL Therapeutics have?
- VBL Therapeutics has 11-50 employees.
- What is VBL Therapeutics' primary sector?
- VBL Therapeutics' primary sector is Health Tech & Life Sciences.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | vblrx.com |
|---|---|
| linkedin.com/company/6282834 | |
| facebook.com/VascularBiogenics | |
| YouTube | youtube.com/channel/UCH7FqeGIzXzvTKsqxWNy6-w |
Identifiers & details
| Founded | 2000-1 |
|---|---|
| Employees (exact) | 14 |
| Market cap | $16.2M |
| Status reason | Acquired by Notable Labs on Feb, 2023 |
Acquisitions & public offerings
Acquired by Notable Labs 2023-02
Radar intelligence
Web history (Wayback)
| Domain | vblrx.com |
|---|
Certificate / subdomain footprint
| Subdomains | 8 |
|---|